Gastroesophageal Reflux Disease: Pharmacotherapy

Recognition and Diagnostic Boundaries

Gastroesophageal reflux disease (GERD) describes reflux that produces troublesome symptoms or complications. Heartburn and regurgitation are typical. Isolated chronic cough, dysphonia, and throat symptoms are nonspecific and should not automatically be treated as GERD. Epigastric-pain predominant dyspepsia warrants a separate assessment, including consideration of peptic ulcer disease and Helicobacter pylori infection (Katz et al., 2022; Zerr & Cornelison, 2026).

Dysphagia, odynophagia, overt gastrointestinal bleeding, anemia, and unexplained weight loss merit diagnostic evaluation. Chest pain first requires appropriate assessment for cardiac and other dangerous causes. Endoscopy is indicated for alarm features and selected Barrett esophagus risk profiles. Persistent symptoms without objective evidence may require ambulatory reflux testing rather than indefinite empiric treatment (Katz et al., 2022; Yadlapati et al., 2022).

Treatment Selection by Clinical Presentation

Clinical situation	Initial approach	Decision point
Infrequent uncomplicated heartburn	Individualized behavioral measures; antacid, alginate-containing product, or intermittent H2-receptor antagonist (H2RA).	Symptom relief alone does not justify indefinite daily PPI therapy.
Troublesome typical GERD, no alarm features	Empiric once-daily PPI for 8 weeks, generally before breakfast (ACG); AGA advises reassessment after 4–8 weeks.	Confirm correct timing, symptom response, and need for continued therapy.
Symptoms remain despite standard-dose PPI	Check adherence, timing, dosing, alternate diagnoses and coexisting disorders; consider one PPI change or clinician-directed twice-daily therapy.	If still unresponsive, pursue objective evaluation; do not layer on medications reflexively.
Los Angeles grade C/D esophagitis or peptic stricture; Barrett esophagus	Maintenance PPI or appropriately selected specialist intervention.	Avoid routine deprescribing in high-risk or complicated GERD.

For typical reflux without alarms, the ACG recommends an 8-week PPI trial; the AGA best-practice update also supports an initial 4–8-week single-dose trial. These are clinical trial periods, not necessarily identical to every product’s FDA-labeled duration (Katz et al., 2022; Yadlapati et al., 2022).

Pharmacologic Classes and Therapeutic Position

Class	Therapeutic rationale	Safety and limitations
Antacids (calcium carbonate; magnesium/aluminum salts)	Rapid neutralization of existing acid; episodic rescue, not sustained healing of erosive esophagitis.	Adverse effects and drug-binding interactions depend on the salt and dose; verify renal suitability and separation from interacting oral drugs using the selected formulation.
Alginates	Form a postprandial physical barrier and may relieve breakthrough regurgitation.	Review the specific alginate formulation and its ingredient list before recommending it.
H2RAs (famotidine; other agents)	Block parietal-cell histamine-2 receptors; useful for episodic or selected nocturnal symptoms.	Less healing efficacy than PPIs; tachyphylaxis with frequent use, renal-dose considerations for famotidine; check the selected H2RA label for other clinically important interactions.
PPIs (omeprazole, pantoprazole, esomeprazole)	Inhibit active parietal-cell H+/K+-ATPase; preferred for frequent GERD and erosive disease.	Scheduled premeal dosing for most formulations; assess indication, interactions and adverse effects.
Motility / adjunctive drugs	Consider only in selected objectively characterized refractory problems.	Do not routinely add prokinetics without gastroparesis; baclofen without objective GERD is not recommended (Katz et al., 2022).

Representative Adult Regimens and Labeled-Use Distinctions

Drug	Example adult regimen	Prescribing qualifier
Omeprazole delayed release	20 mg orally daily, often used in an empiric GERD trial.	Product labeling distinguishes symptomatic GERD from erosive esophagitis and has indication-specific treatment durations. An 8-week empiric trial is a guideline pathway, not necessarily the labeled duration for each phenotype.
Pantoprazole delayed release	40 mg orally daily.	U.S. label: erosive esophagitis with GERD, up to 8 weeks; may repeat a course if not healed. Label indication and duration differ from empiric symptom-based use.
Esomeprazole	20–40 mg orally daily in selected adult GERD phenotypes.	Choose dose by indication, severity and product label; more is not automatically better.
Famotidine	Some OTC famotidine products contain 10 or 20 mg per tablet; prescribed GERD regimens differ. Follow the indication- and formulation-specific label, including renal adjustments.	Confirm formulation and renal function before selecting a scheduled regimen.

Dosage examples represent adults with no specified pregnancy, hepatic, renal or interacting-drug constraints. Verify the exact product formulation and label before prescribing (Proficient Rx LP, 2024; Wyeth Pharmaceuticals LLC, 2026; Zerr & Cornelison, 2026).

Administration, Nonpharmacologic Treatment, and Counseling

• For most conventional delayed-release PPIs, dose 30–60 minutes before breakfast; if prescribed twice daily, give the second dose before the evening meal. Dexlansoprazole and certain formulations have different administration instructions.
• PPIs are not reliable immediate rescue drugs. A single dose does not test maximal acid suppression. Check adherence, timing, and access before escalation.
• Recommend weight reduction when appropriate, avoiding meals within 2–3 hours of bedtime, and head-of-bed elevation for nocturnal symptoms. Identify patient-specific triggers rather than prescribing universal food avoidance.
• Review NSAIDs, antiplatelets, anticoagulants, clopidogrel/PPI interaction considerations, OTC antacids, supplements, and medications whose absorption depends on gastric acidity. Separate mineral-based antacids from interacting drugs by product-specific instructions.

Monitoring and Response-Based Decisions

• Reassess within 4–8 weeks: heartburn/regurgitation frequency, nighttime waking, adherence, correct dose timing, function, adverse effects, and whether the original diagnosis remains plausible.
• If uncontrolled, verify use and assess alternative or overlapping diagnoses. For optimized nonresponse, endoscopy and ambulatory reflux testing may be indicated; isolated extraesophageal symptoms often warrant testing before a PPI trial.
• Attempt discontinuation, on-demand dosing or lowest-effective-dose maintenance after resolution of uncomplicated GERD without a long-term indication. Counsel on possible transient rebound acid hypersecretion.
• Continue appropriately indicated therapy for Barrett esophagus, severe erosive esophagitis, peptic stricture, and patients at high risk for upper GI bleeding. Reassess twice-daily therapy for possible step-down to once daily, not automatic discontinuation.

PPI safety requires proportional interpretation. Observational associations with chronic kidney disease, fractures, dementia, micronutrient abnormalities and infections do not establish that PPIs cause each outcome. Do not stop clinically indicated treatment solely because of theoretical adverse events; investigate patient-specific risks and symptoms as warranted (Katz et al., 2022; Targownik et al., 2022).

Drug-Interaction Discriminator: Clopidogrel and PPI Choice

The U.S. Plavix label advises avoiding omeprazole or esomeprazole with clopidogrel because CYP2C19 inhibition reduces formation of its active metabolite and decreases platelet inhibition. Separating administration by 12 hours does not resolve the interaction. If gastroprotection is indicated, coordinate selection of a different acid-suppressive agent; pantoprazole and certain other PPIs have less effect on clopidogrel antiplatelet activity. Do not abruptly stop gastroprotection in a patient at high GI-bleeding risk (Sanofi-Aventis U.S. LLC, 2025).

A patient with coronary stents taking clopidogrel and a newly started omeprazole should receive an indication and drug-interaction review rather than being told to take the agents at opposite times. Antithrombotic therapy and GI protection both require a deliberate plan (Sanofi-Aventis U.S. LLC, 2025).

Special Populations and Diagnostic Exceptions

Infants: Uncomplicated regurgitation with normal growth is usually physiologic and does not justify empiric PPI treatment. Evaluate feeding, growth, and alternative etiologies; maintain safe supine sleep regardless of reflux (Moon et al., 2022). Children with recurrent symptoms or inability to discontinue therapy warrant pediatric-specific evaluation (Zerr & Cornelison, 2026).

Pregnancy: Evaluate alarm symptoms and try nonpharmacologic measures before selecting acid suppression. Pregnancy and lactation require product-specific review, including the actual ingredients and timing of exposure; do not extrapolate a safety conclusion from one formulation to an entire drug class. Lactation: Available LactMed evidence suggests relatively low infant exposure to famotidine and to omeprazole 20 mg/day, but the omeprazole evidence is limited and does not support extrapolation to all PPIs or doses. Select according to indication and maternal/infant circumstances (National Institute of Child Health and Human Development, 2022, 2024; Zerr & Cornelison, 2026).

Vonoprazan: A Distinct Acid-Suppression Option

Vonoprazan is a potassium-competitive acid blocker (P-CAB), not a PPI. The U.S. labeled single-agent tablet regimens distinguish healing of erosive esophagitis (20 mg once daily for 8 weeks), maintenance after healing (10 mg once daily for up to 6 months), and relief of heartburn associated with nonerosive GERD (10 mg once daily for 4 weeks). It can be taken without the premeal timing required for many PPIs; confirm renal/hepatic adjustments, contraindications (including rilpivirine), interactions, access and formulary cost in the current label. These GERD regimens are not interchangeable with a vonoprazan-amoxicillin H. pylori pack (Phathom Pharmaceuticals Inc., 2026).

For patients with uncomplicated typical symptoms, a correctly administered PPI still has an established guideline-supported first-line role. Consider a P-CAB when a specific indication and patient factors support it rather than presenting it as universally superior or assuming access. The treatment decision should name the phenotype, evidence, intended duration and monitoring target (Katz et al., 2022; Phathom Pharmaceuticals Inc., 2026).

Refractory Symptoms: Determine Whether Reflux Actually Persists

First verify that the PPI was taken daily at the appropriate premeal time for an adequate duration, assess adherence and consider one optimized twice-daily course when indicated. Review alternative explanations such as esophageal motility disorders, rumination, eosinophilic esophagitis, dyspepsia and functional heartburn before indefinite dose escalation (Katz et al., 2022).

If GERD has never been objectively established, reflux monitoring OFF acid suppression is generally used to establish abnormal reflux. If objective GERD is already present and bothersome symptoms continue despite optimized twice-daily PPI, impedance-pH testing ON therapy can assess persistent acid and nonacid reflux and symptom association. Normal reflux exposure with no association supports functional heartburn; physiologic exposure with positive association supports reflux hypersensitivity. Neither diagnosis is treated simply by escalating acid suppression. Referral is appropriate when testing, motility evaluation or an invasive strategy is being considered (Katz et al., 2022).

Maintenance Selection and a Measurable Reassessment Plan

At the initial visit document weekly symptomatic episodes, nocturnal waking, regurgitation, dysphagia, bleeding or weight loss, functional impact, drug timing and adherence. At 4–8 weeks assess improvement, tolerability and whether an objective long-term indication exists. After symptom resolution without erosive complications, discuss step-down or discontinuation rather than indefinite automatic renewal. Severe erosive disease, Barrett esophagus or recurrent complications may justify sustained acid suppression with follow-up. Long-term safety discussions should distinguish causal harms from observational associations (Targownik et al., 2022; Yadlapati et al., 2022).

Decision pathway: Persistent symptom phenotype

Persistent symptom phenotype	Next decision	Unhelpful response
Unproven GERD; persistent heartburn despite optimized PPI	Consider endoscopy and reflux monitoring OFF PPI to establish or exclude pathologic reflux.	Escalating acid suppression indefinitely without objective confirmation.
Proven erosive GERD; regurgitation despite adequate BID PPI	Consider impedance-pH ON PPI and motility work-up if intervention is contemplated.	Assuming every symptom represents continued acid exposure.
Normal acid exposure and negative reflux-symptom association	Reconsider diagnosis; consider functional heartburn and appropriate neuromodulation/behavioral approaches.	Repeated unnecessary PPI changes.
Healed erosive esophagitis or controlled uncomplicated GERD	Maintain if complication risk requires, otherwise step down when appropriate.	Indefinite high-dose acid suppression without documented indication.

Applied Clinical Case and Prescribing Rationale

Scenario: A 62-year-old with coronary stent taking clopidogrel reports nightly regurgitation despite omeprazole, taken immediately before bed. There is no dysphagia or bleeding. What comes first?

Reasoned response: Clarify symptom phenotype and optimize a guideline-supported GERD regimen, but also reconcile the clopidogrel interaction: avoid omeprazole/esomeprazole where alternatives are appropriate and coordinate antiplatelet therapy rather than simply separating doses. Reassess response after a defined trial. If refractory symptoms persist after an adequate regimen, select on/off-PPI testing according to whether GERD has been objectively demonstrated (Katz et al., 2022; Sanofi-Aventis U.S. LLC, 2025).

High-Yield Distinctions

Related YourDNP Resources

Pharmacology learning hub · Peptic Ulcer Disease · H. pylori Eradication

---

---

References

Katz, P. O., Dunbar, K. B., Schnoll-Sussman, F. H., Greer, K. B., Yadlapati, R., & Spechler, S. J. (2022). ACG clinical guideline for the diagnosis and management of gastroesophageal reflux disease. American Journal of Gastroenterology, 117(1), 27–56. https://doi.org/10.14309/ajg.0000000000001538

Moon, R. Y., Carlin, R. F., & Hand, I. (2022). Sleep-related infant deaths: Updated 2022 recommendations for reducing infant deaths in the sleep environment. Pediatrics, 150(1), e2022057990. https://doi.org/10.1542/peds.2022-057990

National Institute of Child Health and Human Development. (2022, May 15). Omeprazole. In Drugs and Lactation Database (LactMed). National Library of Medicine. https://www.ncbi.nlm.nih.gov/books/NBK501242/

National Institute of Child Health and Human Development. (2024, August 15). Famotidine. In Drugs and Lactation Database (LactMed). National Library of Medicine. https://www.ncbi.nlm.nih.gov/books/NBK501267/

Phathom Pharmaceuticals Inc. (2026, July 16). Voquezna (vonoprazan) tablets [Prescribing information]. DailyMed. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0cc52ac5-77ec-4d66-a770-762a1a960914

Proficient Rx LP. (2024). Omeprazole delayed-release capsules [Prescribing information]. DailyMed. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=03ac077f-3873-4087-96d0-89049161dea9

Sanofi-Aventis U.S. LLC. (2025, May 30). Plavix (clopidogrel bisulfate) tablets [Prescribing information]. DailyMed. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de8b0b67-eb25-4684-83b5-7ad785314227

Targownik, L. E., Fisher, D. A., & Saini, S. D. (2022). AGA clinical practice update on de-prescribing of proton pump inhibitors: Expert review. Gastroenterology, 162(4), 1334–1342. https://doi.org/10.1053/j.gastro.2021.12.247

Wyeth Pharmaceuticals LLC. (2026, May 18). Protonix (pantoprazole sodium) delayed-release tablets [Prescribing information]. DailyMed. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=08098cb2-c048-4640-f387-6beec4a38936

Yadlapati, R., Gyawali, C. P., & Pandolfino, J. E. (2022). AGA clinical practice update on the personalized approach to the evaluation and management of GERD: Expert review. Clinical Gastroenterology and Hepatology, 20(5), 984–994.e1. https://doi.org/10.1016/j.cgh.2022.01.025

Zerr, B., & Cornelison, B. (2026). Gastroesophageal reflux disease. In M. A. Chisholm-Burns, P. M. Malone, J. M. Kolesar, K. C. Lee, P. B. Bookstaver, & K. R. Matthias (Eds.), Pharmacotherapy principles & practice (7th ed., Chapter 18). McGraw Hill.